Management of Decompensated Cirrhosis in ICU with Delirium Tremens

This patient requires immediate aggressive management of delirium tremens with benzodiazepines, broad-spectrum antibiotics (ceftriaxone 1g daily), discontinuation of all diuretics and beta-blockers, albumin infusion for volume expansion and renal protection, correction of severe hyponatremia with fluid restriction, and urgent evaluation for liver transplantation given the high MELD score and multiple organ dysfunction.

Immediate Priorities

1. Delirium Tremens Management

Administer high-dose benzodiazepines (lorazepam or diazepam) using symptom-triggered or fixed-schedule protocols
Monitor for seizures and cardiovascular instability
Thiamine 500mg IV before any glucose administration
Folate and multivitamin supplementation

2. Infection Screening and Prophylaxis

Start empiric antibiotics immediately - infection is the most common precipitant of acute-on-chronic liver failure (ACLF) and is present in 48% of cases 1. This patient has multiple high-risk features: alcohol-associated cirrhosis, ICU admission, and decompensation.

Ceftriaxone 1g IV daily for 7 days - first-line choice in advanced cirrhosis 2
Perform diagnostic paracentesis if ascites present (check cell count, culture, gram stain)
Blood cultures, urinalysis and culture, chest X-ray
Screen for spontaneous bacterial peritonitis (SBP), pneumonia, urinary tract infection

Critical caveat: Fever is often absent in cirrhotic patients with sepsis. New or worsening mental status, hyponatremia, or AKI frequently signal infection 1.

3. Acute Kidney Injury Management

With creatinine likely elevated (implied by clinical context), discontinue all diuretics immediately 2. The elevated INR (2.5) and thrombocytopenia suggest advanced disease with high risk for hepatorenal syndrome (HRS-AKI).

Stop all nephrotoxic drugs: NSAIDs, aminoglycosides, ACE inhibitors, beta-blockers 2
Albumin 1g/kg (max 100g) IV for 2 consecutive days if AKI stage >1A without obvious cause 2
Volume expansion with crystalloids if hypovolemia suspected
If HRS-AKI diagnosed: terlipressin plus albumin or norepinephrine (preferred if shock present) 1, 2

4. Severe Hyponatremia (Na 125)

This hypervolemic hyponatremia indicates advanced disease with poor prognosis and requires careful management 2.

Fluid restriction (not hypertonic saline unless life-threatening symptoms like seizures)
Avoid rapid correction (risk of osmotic demyelination)
Target increase <10-12 mEq/L in 24 hours
Hypertonic saline only for severe symptomatic hyponatremia with cardiorespiratory distress, seizures, or coma 2

5. Anemia Management (Hgb 8.3)

Transfuse to maintain hemoglobin 7-9 g/dL using a restrictive strategy 2. This patient may have occult GI bleeding given the clinical context.

Screen for variceal bleeding with upper endoscopy once hemodynamically stable
Avoid over-transfusion (increases portal pressure)
If active bleeding: octreotide or terlipressin plus endoscopic band ligation 2

6. Coagulopathy (INR 2.5, Platelets 75)

Do NOT routinely correct INR with FFP or platelets unless active bleeding or invasive procedure planned. The elevated INR reflects synthetic dysfunction, not bleeding risk in isolation.

Vitamin K 10mg IV × 3 days (may help if nutritional deficiency)
For procedures: consider thresholds of platelets >50,000 and INR <2.0, but individualize

7. Hepatic Encephalopathy Risk

With delirium tremens, distinguishing from hepatic encephalopathy is challenging but both may coexist.

Lactulose 20-30g PO/NG every 2-4 hours until bowel movement, then titrate to 2-3 soft stools daily
Rifaximin 550mg PO twice daily (add to lactulose for synergistic effect)
Avoid sedatives when possible (benzodiazepines necessary for DTs but monitor closely)
Screen for precipitating factors: infection, GI bleeding, constipation, hyponatremia 3

Risk Stratification and Prognosis

Calculate MELD-Na score immediately - with bilirubin 13.6, INR 2.5, creatinine (unknown but likely elevated), and sodium 125, this patient likely has MELD >25, indicating:

High short-term mortality (>50% at 3 months without transplant)
Urgent transplant evaluation needed

Assess for ACLF (Acute-on-Chronic Liver Failure) 1:

This patient has multiple organ failures: liver (bilirubin 13.6), likely kidney (hyponatremia, clinical context), coagulation (INR 2.5), brain (encephalopathy/DTs)
ACLF-2 or ACLF-3 carries 30-day mortality of 32-77%

Critical Pitfalls to Avoid

Do NOT give NSAIDs - high risk of AKI, sodium retention, and diuretic resistance 2
Do NOT continue beta-blockers - should be stopped during acute decompensation and AKI 2
Do NOT use aminoglycosides except in specific resistant infections 2
Do NOT use starch for volume expansion - associated with worse outcomes 2
Do NOT delay antibiotics - even without confirmed infection, prophylaxis improves survival in this high-risk patient 1, 2
Do NOT correct INR routinely - does not reduce bleeding risk and wastes resources

Liver Transplant Evaluation

Refer urgently to transplant hepatology - this patient meets criteria for expedited evaluation:

Decompensated cirrhosis with multiple complications
High MELD score
Alcohol-associated cirrhosis (requires 6-month abstinence documentation at most centers, but exceptions exist for severe ACLF)

Monitoring Parameters

Hourly: vital signs, mental status (CIWA-Ar for DTs)
Every 4-6 hours: electrolytes, renal function
Daily: liver function tests, CBC, coagulation studies
Continuous: cardiac monitoring, fluid balance

Disposition

This patient requires ICU-level care with hepatology consultation. The combination of delirium tremens, severe decompensated cirrhosis, and multiple organ dysfunction creates extremely high mortality risk (likely >50% in-hospital mortality) 3. Early aggressive management of all complications simultaneously, rather than sequential treatment, is essential for survival.

Have a follow-up question?